Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Peking University Cancer Hospital & Institute is the lead sponsor of 80 current clinical trials in our China register. 50 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are 18F-FDG, Cisplatin and Adebrelimab. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting5063%
Not yet open2734%
Active, closed23%
By invitation11%

Trials by phase

Phase 22936%
Observational2025%
Not applicable1418%
Phase 1810%
Phase EARLY_PHASE134%
Phase 334%
Phase 1/223%
Phase 2/311%

Clinical trials sponsored by Peking University Cancer Hospital & Institute

80 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe NCT06203119 · ClinicalTrials.gov ↗ · Cancer Drug: 18F-FDG	Phase 1	Recruiting	2024-03	China
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer) Drugs: Albumin paclitaxel, Carboplatin, Cisplatin	Phase 1	Recruiting	2025-05	China
Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer NCT06306755 · ClinicalTrials.gov ↗ · Esophageal Cancer, Gastric Cancer, Precision Screening	Not applicable	Recruiting	2024-06	China
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma NCT06869213 · ClinicalTrials.gov ↗ · Esophageal Cancer (EsC) Drugs: Adebrelimab, Cisplatin, Nab-paclitaxel	Phase 2	Recruiting	2025-03	China
Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. NCT06894797 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Not applicable	Recruiting	2025-04	China
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab NCT06141265 · ClinicalTrials.gov ↗ · Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Drug: Niraparib	Phase 2	Recruiting	2023-11	China
Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach NCT07178340 · ClinicalTrials.gov ↗ · Hepatoid Adenocarcinoma of Stomach	Phase 2	Recruiting	2025-09	China
A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy NCT06549907 · ClinicalTrials.gov ↗ · MSS Metastatic Colorectal Cancers, MSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy	Observational	Recruiting	2024-01	China
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy NCT06869239 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC) Drugs: Cisplatin/carboplatin, Etoposide	Observational	Recruiting	2025-02	China
Al18F-HER2-BCH PET in Breast Patients Treated With ADC Therapy NCT06909604 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Recruiting	2025-01	China
Immunotherapy Combined with Hypofractionated Concurrent Chemoradiotherapy Followed by Immunotherapy in LA-NSCLC NCT06849167 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	2025-03	China
Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma NCT06211114 · ClinicalTrials.gov ↗ · Collecting Duct Carcinoma Drug: Axitinib	Phase 2	Recruiting	2024-02	China
A Phase I Study to Evaluate the Safety and Preliminary Efficacy of [225Ac]Ac-DOTATATE Injection Combined With Tislelizumab in the Maintenance Treatment Period for Patients of Extensive-stage Small Cell Lung Cancer (ES-SCLC) With Somatostatin Receptors (SSTR)+ as First-line Treatment NCT07413042 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1	Recruiting	2026-01	China
A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma NCT06313957 · ClinicalTrials.gov ↗ · Relapsed B-cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma	Phase 1	Recruiting	2024-03	China
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression NCT06420973 · ClinicalTrials.gov ↗ · Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma	Phase 2	Recruiting	2024-05	China
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer NCT05104788 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Icotinib	Phase 2	Recruiting	2021-10	China
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors NCT06728189 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1	Recruiting	2024-11	China
Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration NCT06991790 · ClinicalTrials.gov ↗ · TNBC Drugs: Sacituzumab Govitecan, Toripalimab	Observational	Recruiting	2025-05	China
Trop-2 Targeted PET Probes in Advanced TNBC NCT07046455 · ClinicalTrials.gov ↗ · TNBC - Triple-Negative Breast Cancer	Not applicable	Recruiting	2025-03	China
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study NCT07251868 · ClinicalTrials.gov ↗ · Breast Cancer, Brain Metastases From Breast Cancer, Trop2 Drug: Sacituzumab Govitecan	Observational	Recruiting	2024-08	China
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With SSTR+ GEP-Nens NCT06732505 · ClinicalTrials.gov ↗ · Neuroendocrine Neoplasm	Phase 1	Recruiting	2024-09	China
Radiolabelled Nectin-4 Targeted LMW Probe PET/CT in Patients With Lung Lesions NCT06648317 · ClinicalTrials.gov ↗ · Lung Cancer, Non-Small Cell, Lung Infection	Observational	Recruiting	2024-11	China
Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors NCT06454955 · ClinicalTrials.gov ↗ · B7H3, CD276 Affibody, PET/CT Imaing	Phase EARLY_PHASE1	Recruiting	2024-01	China
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC NCT06360042 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma Drugs: Adebrelimab, Apatinib, Bevacizumab	Phase 2	Recruiting	2024-01	China
Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma NCT05789043 · ClinicalTrials.gov ↗ · Acral Melanoma Drugs: Apatinib, Camrelizumab	Phase 3	Recruiting	2023-03	China
A Phase II Study of Dexamethasone, Azacitidine, Pegaspargase and Tislelizumab Plus Radiotherapy for Patients With Stage I/II Extranodal NK/T-cell Lymphoma NCT07000617 · ClinicalTrials.gov ↗ · NK/T Cell Lymphoma	Phase 2	Recruiting	2025-03	China
Clinical Application of CAIX-Targeted PET Imaging in Tumors NCT07590310 · ClinicalTrials.gov ↗ · Kidney Cancers	Phase EARLY_PHASE1	Recruiting	2025-03	China
HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC NCT06548529 · ClinicalTrials.gov ↗ · HER2 Positive or Suspicious Positive Tumors	Not applicable	Recruiting	2024-06	China
Adaptive Therapy for Resected Stage ⅠA2-Ⅱ NSCLC Patients With Undetectable MRD NCT06924710 · ClinicalTrials.gov ↗ · NSCLC	Not applicable	Recruiting	2025-04	China
Circulating Tumor DNA Guided Adjuvant Chemotherapy for Colon Cancer NCT05529615 · ClinicalTrials.gov ↗ · Colon Cancer, Circulating Tumor DNA	Not applicable	Recruiting	2022-11	China
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors NCT05579275 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase EARLY_PHASE1	Recruiting	2023-02	China
MMP14(MT1-MMP) Targeting Bicyclic Peptide Probe for PET Imaging in Solid Tumors NCT06719856 · ClinicalTrials.gov ↗ · Solid Tumor Drug: 18-FDG	Observational	Recruiting	2025-01	China
KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade NCT06099821 · ClinicalTrials.gov ↗ · Digestive System Cancers Drugs: Apatinib, KN046, Regorafenib	Phase 2	Recruiting	2023-10	China
Organ Preservation First Strategy and Intentional Watch and Wait for MRI Defined Low-risk Rectal Cancer NCT06209099 · ClinicalTrials.gov ↗ · Rectal Cancer	Not applicable	Recruiting	2024-01	China
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular Imaging NCT06715020 · ClinicalTrials.gov ↗ · Breast Cancer Drug: 18F-FDG	Not applicable	Recruiting	2024-12	China
A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery NCT06674252 · ClinicalTrials.gov ↗ · Lung Cancers	Not applicable	Recruiting	2025-06	China
A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer NCT06869226 · ClinicalTrials.gov ↗ · Esophageal Cancer Drugs: Camrelizumab, Cisplatin, Nab-paclitaxel	Phase 2	Recruiting	2025-04	China
Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer NCT06926179 · ClinicalTrials.gov ↗ · Lung Cancer (NSCLC), Neoadjuvant Immunotherapy, Radiotherapy	Observational	Recruiting	2024-12	China
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy NCT07724535 · ClinicalTrials.gov ↗ · Cancer	Phase 1/2	Recruiting	2026-06	China
Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma NCT05321316 · ClinicalTrials.gov ↗ · Urothelial Carcinoma Drug: 18F-FDG	Not applicable	Recruiting	2026-05	China
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer NCT05985109 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	2023-10	China
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors NCT07529002 · ClinicalTrials.gov ↗ · Solid Tumors	Observational	Recruiting	2026-04	China
Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) NCT06229041 · ClinicalTrials.gov ↗ · Rectal Cancer	Phase 3	Recruiting	2023-03	China
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer NCT06768307 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage, Immunotherapy, Chemotherapy	Phase 2	Recruiting	2025-01	China
Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma NCT05512481 · ClinicalTrials.gov ↗ · Melanoma, Acral Melanoma, Temozolomide	Phase 2	Recruiting	2022-09	China
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors NCT05436093 · ClinicalTrials.gov ↗ · Solid Tumor Drug: 18F-FDG	Not applicable	Recruiting	2022-06	China
Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure NCT07087223 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer NSCLC Drugs: Furmonertinib, Vebreltinib	Phase 1/2	Recruiting	2025-04	China
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma NCT04047953 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma Drugs: Oxaliplatin and S-1, Paclitaxel	Not applicable	Recruiting	2019-09	China
Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach NCT06992362 · ClinicalTrials.gov ↗ · Hepatoid Adenocarcinoma of Stomach	Phase 2	Recruiting	2025-05	China
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC NCT05917431 · ClinicalTrials.gov ↗ · Unresectable Hepatocellular Carcinoma, Oligometastatic Disease	Phase 2	Recruiting	2023-06	China
Chinese Ostomy Collaboration Group (COCG) Clinical Study -SITI Classification NCT07111429 · Complication,Postoperative, Stoma	Observational	Not yet open	2025-08	China
Retlirafusp Alfa Plus Targeted Therapy and Chemotherapy for Unresectable Colorectal Liver-Limited Metastases NCT07815288 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma Metastatic in the Liver Drug: Retlirafusp alfa	Phase 2	Not yet open	2026-09	China
Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer NCT06784206 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy	Phase 2	Not yet open	2025-02	China
CD147 Targeting Peptide Probe for PET Imaging in Solid Tumors NCT06720298 · ClinicalTrials.gov ↗ · Solid Tumor Drug: 18F-FDG	Observational	Not yet open	2025-01	China
Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone NCT07381543 · ClinicalTrials.gov ↗ · Localized Small Cell Lung Cancer	Phase 2	Not yet open	2026-03	China
SHR-A1904 in Advanced Colorectal Cancer: an Exploratory Study NCT07700719 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic	Phase 2	Not yet open	2026-07	China
Evaluating AI and Human Expert Decisions in Colorectal Cancer NCT07045207 · ClinicalTrials.gov ↗ · Colorectal Cancer	Observational	Not yet open	2025-07	China
68Ga-HSA PET/CT Imaging for Protein-losing Enteropathy NCT06716788 · ClinicalTrials.gov ↗ · Cancer	Observational	Not yet open	2025-05	China
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma NCT04622566 · ClinicalTrials.gov ↗ · Mucosal Melanoma, Neoadjuvant Treatment Drugs: Lenvatinib, Pembrolizumab	Phase 2	Not yet open	2020-12	China
JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma NCT07024147 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma, Large B Cell Diffuse Lymphoma, Follicular Lymphoma Drugs: Cyclophosphamide, Fludarabine	Phase 1	Not yet open	2025-07	China
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis NCT07007728 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Secondary Malignant Neoplasm of Liver Drugs: Bevacizumab, Capeox, Iparomlimab and Tuvonralimab	Phase 2	Not yet open	2025-06	China
Development and Validation of a Colorectal Cancer Diagnostic Model NCT07692555 · ClinicalTrials.gov ↗ · Colorectal Cancer, Advanced Neoplasia, Prediction Models	Observational	Not yet open	2026-07	China
Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery NCT07822906 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Observational	Not yet open	2026-10	China
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma NCT05985707 · ClinicalTrials.gov ↗ · HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer	Phase 2	Not yet open	2023-08	China
High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC NCT07182708 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer), EGFR Activating Mutation, Resectable Lung Non-Small Cell Carcinoma Drugs: Bevacizumab, Firmonertinib Mesilate	Phase 2	Not yet open	2025-10	China
Neoadjuvant Fruquintinib Plus Tislelizumab Combined With mCapeOX Versus CapeOX for Mid-high pMMR/MSS Locally Advanced Rectal Cancer NCT06443671 · ClinicalTrials.gov ↗ · Rectal Cancer Drug: Capeox	Phase 2/3	Not yet open	2024-06	China
5T4 Targeting Nanobody Probe for PET Imaging in Solid Tumors NCT07589101 · ClinicalTrials.gov ↗ · Lung Cancer, Breast Cancer Drug: 18F-FDG	Not applicable	Not yet open	2026-06	China
Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC NCT07200154 · ClinicalTrials.gov ↗ · Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy	Phase 2	Not yet open	2025-09	China
TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors NCT06755086 · ClinicalTrials.gov ↗ · Solid Tumors	Observational	Not yet open	2025-01	China
Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD NCT07357532 · ClinicalTrials.gov ↗ · Small Cell Lung Carcinoma Drugs: Adebrelimab, Apatinib Mesylate	Phase 2	Not yet open	2026-01	China
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer NCT06745219 · ClinicalTrials.gov ↗ · Thrombopenia, Cervical Cancer, Radiotherapy Side Effect Drug: Herombopag	Phase 2	Not yet open	2025-01	China
EGFR Mutation Targeting Molecular Probe for PET Imaging NCT06641674 · ClinicalTrials.gov ↗ · Cancer	Observational	Not yet open	2024-11	China
Non-Operative Management and Following Immunotherapy for Colorectal Cancer and Other GI Cancers NCT07656740 · ClinicalTrials.gov ↗ · Gastrointestinal Cancer, Colorectal (Colon or Rectal) Cancer, Stomach (Gastric) Cancer	Observational	Not yet open	2026-06	China
A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI NCT07165418 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma (RCC) Drugs: Everolimus, Sunitinib, Vorolanib	Phase 3	Not yet open	2025-09	China
Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD NCT06780839 · ClinicalTrials.gov ↗ · NSCLC, Stage I, II, IIIA, IIIB Drug: Ensartinib	Phase 2	Not yet open	2025-01	China
Efficacy and Biomarkers of the Second-line Treatment of Adebelizumab Combined With Irinotecan Liposome in Advanced Small Cell Lung Cancer NCT07004712 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Drug: Adebelizumab	Phase 2	Not yet open	2025-06	China
SLNB Combined With WLNB for Axillary De-escalation in Breast Cancer Patients With Abnormal Axillary Nodes NCT07791771 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Not yet open	2026-07	China
A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma NCT06424626 · ClinicalTrials.gov ↗ · Melanoma, Mucosal Melanoma, Metastatic Melanoma Drugs: Axitinib, Cadonilimab, Ivonescimab	Phase 1	By invitation	2024-05	China
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer NCT07745322 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms	Observational	Active, closed	2026-05	China
Real-world Study of Sacituzumab Govitecan Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer NCT07018427 · ClinicalTrials.gov ↗ · Breast Neoplasms, Triple Negative Breast Cancer, HR+, HER2-, Advanced Breast Cancer Drug: Sacituzumab Govitecan	Observational	Active, closed	2023-05	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Peking University Cancer Hospital & Institute trials

43 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

+ 3 more in the trial list above.

Conditions in Peking University Cancer Hospital & Institute trials

106 conditions

Breast Cancer6 Cancer4 Solid Tumor3 Colorectal Cancer3 Rectal Cancer3 Esophageal Cancer2Hepatoid Adenocarcinoma of Stomach2Non-Small Cell Lung Cancer2 SCLC, Extensive Stage2Mucosal Melanoma2Melanoma2 Unresectable Hepatocellular Carcinoma2 Solid Tumors2Acral Melanoma2Radiotherapy2Complication,Postoperative1Stoma1NSCLC (Advanced Non-small Cell Lung Cancer)1 Gastric Cancer1Precision Screening1Sequential Screening1Esophageal Cancer (EsC)1Locally Advanced Rectal Cancer1Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma1

By trial register

Register	Trials	Recruiting
Clinical trials in China	80	50

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Peking University Cancer Hospital & Institute trials

How many clinical trials does Peking University Cancer Hospital & Institute sponsor?

Peking University Cancer Hospital & Institute is the lead sponsor of 80 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Peking University Cancer Hospital & Institute trials recruiting?

Yes. 50 of its 80 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Peking University Cancer Hospital & Institute testing?

Its current trials name 43 drugs and biologicals as interventions. The most frequent are 18F-FDG (6), Cisplatin (4), Adebrelimab (3), Apatinib (3) and Bevacizumab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Peking University Cancer Hospital & Institute clinical trials